India Glycols Limited (INDIAGLYCO) fair value: what the stock is really worth
As of Sep 30, 2026: fair value of India Glycols Limited ₹325, price ₹307, upside +5.9%, quality 32 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
Watch India Glycols Limited for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card.Watch for freePro now: $1 first month
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 27, 2026.
How to read this chart
60‑month range ₹236.20 – ₹1,203 · fair‑value band ₹227.76 – ₹422.99 · the ₹307.40 price screens below the ₹325.38 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Sep 27, 2026.
Follow India Glycols in your weekly email
Every Wednesday you see whether India Glycols is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
India Glycols Limited, a green petrochemical company, manufactures and sells industrial chemicals in India. It operates through Bio-based Specialities and Performance Chemicals, Potable Spirits, and Ennature Biopharma segments.
Show more
India Glycols Limited, a green petrochemical company, manufactures and sells industrial chemicals in India. It operates through Bio-based Specialities and Performance Chemicals, Potable Spirits, and Ennature Biopharma segments. The company offers bio mono ethylene, di ethylene, and tri ethylene glycols; ethyl/butyl glycol ethers and acetates, and brake fluids; bio-polymers comprising guar and natural gums; biofuels; specialty chemicals, such as plasticisers, oil fields chemicals, bio-amines, methyl soyate, MDEA and MDEA derivatives, bio-potash granules, and C-Smart specialty products; molasses and grain based extra neutral alcohol; and specialty gases, including industrial and medical oxygen, food grade and industrial carbon dioxide, liquid argon and nitrogen, ethylene oxide, and bio ethylene oxide. It also provides Indian made foreign liquor, such as whiskey under Soulmate Blu and Single Reserve brands; vodka under Amazing brand; and rum under Zumba and Beach House XXX brands, as well as economy spirits under Bunty brand, and branded country liquor. In addition, the company offers natural active pharmaceutical ingredients, nutraceuticals, standardized botanical extracts, and nicotine derivatives. Further, its products find applications in pharma and healthcare; textiles; automotive; personal care; industrial and manufacturing; paints and coatings; oil and gas; food ingredients; packaging; potable spirits; and other various industries. The company also exports its products. The company was formerly known as UP Glycols Limited and changed its name to India Glycols Limited in August 1986. India Glycols Limited was incorporated in 1983 and is headquartered in Noida, India.
Stock analysis
India Glycols Limited (INDIAGLYCO) currently trades at ₹307.40, while our model-based Fair Value estimate is ₹325.38, so the stock looks roughly fairly valued today (gap 5.5%).
Show more
Valuation
Bull case: the Multiples group reads highest at a median of ₹742.53 per share, and 13 of the 16 models we run sit above the ₹307.40 price.
Bear case: the Dividend Discount group reads lowest at ₹143.69, and 3 of the 16 models stay below the price. Evidence for this calculation is medium.
Scenario range: ₹227.76 (bear) to ₹422.99 (bull), the price of ₹307.40 sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 32/100 (below-average quality), in the Basic Materials sector.
Expensive Growth: The company is growing, but growth may require heavy reinvestment or weak cash conversion.
India Glycols Limited reported revenue of ₹42.1B in FY2026 versus ₹28.7B in FY2022, a compound +10.1%/yr. Reported net income was ₹2.9B in FY2026, compounding −3.7%/yr from FY2022.
Key figures
Market cap ₹72.1B (≈ $752M) · P/E ratio 23.4 · P/S ratio 1.63 · EPS (TTM) ₹45.97 · Dividend yield 1.0% · Net margin 7.0% · Return on equity 11.3% · Return on assets (EBIT) 8.1%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 37 out of 100 (low confidence).
What moves the price
The share trades about 74% below its 52-week high and 30% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Basic Materials peers we cover trades at −25% fair-value upside, at 6%, INDIAGLYCO screens cheaper than that median.
Fair Value models
Bear ₹227.76Fair Value ₹325.38Bull ₹422.99
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Based on fiscal year 2026 figures (about 6 months old). Earnings retained since then (₹23.17 per share) are deliberately not added.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.50/100
The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Revenue growth 1 year
+11.8%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+16.9%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+12.9%
Start year 2021 (pandemic). Over 10 years: +6.1% a year
Revenue growth 21 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+10.1%
’15
’16
’17
’18
’19
’20
’21
’22
’23
’24
’25
’26
What shareholders gained per year (last 5 years), in INR ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate. Measured in INR: this currency has depreciated against the euro and dollar over the long run, so part of the nominal rate is currency erosion that never reaches a EUR/USD investor.
+2.6%
Earnings growth per share plus dividend.
Earnings per share, growth per year+1.6%
Dividend (yield on the price)1.0%
Pace: 5 vs 10 years ⓘTwo data points, not a trend model: earnings growth per share over the last 5 fiscal years against the last 10. Labelled "steady" when both rates are within 3 percentage points of each other, otherwise picking up or flattening. Shown only when ten years of history exist.1.6% vs 15.0%, slowing
Profit margin 2021 to 2026 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.9% → 12%
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Chemicals · 352 stocks
Beats the industry median on 7/13 measures
A mixed picture versus its industry peers.
Valuation
Quality Score32 · Bottom 25%
Fair Value upside+5.8% · Above median
Profitability
Return on equity (TTM)11.3% · Top 25%
Return on assets4.9% · Above median
Net margin (TTM)7.0% · Above median
Operating margin (TTM)12.8% · Above median
Growth and dividend
Revenue growth13.1% · Above median
Dividend yield (TTM)1.0% · Below median
Balance sheet
Debt / equity0.31× · Above median
Valuation Multiplesvs Chemicals median · lower = cheaper
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Is India Glycols Limited (INDIAGLYCO) overvalued or undervalued?
As of Sep 27, 2026, our model estimates a fair value of ₹325.38 versus a price of ₹307.40, about +6% upside (fairly valued).
What is the fair value of INDIAGLYCO?
Our model-based fair value for India Glycols Limited is ₹325.38 (as of Sep 27, 2026), built from audited fundamentals. The current price: ₹307.40.
What is the quality score of INDIAGLYCO?
India Glycols Limited has a Quality Score of 32/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for India Glycols Limited (INDIAGLYCO)?
Our model-based price target is the fair value of ₹325.38 (as of Sep 27, 2026) from 16 valuation models. Cautious scenario ₹227.76, optimistic scenario ₹422.99. It is a calculation from audited fundamentals, not an analyst target.
What is the India Glycols Limited stock forecast for 2026?
Our models put fair value at ₹325.38, about +6% upside versus a price of ₹307.40 (fairly valued). Cautious scenario ₹227.76, optimistic scenario ₹422.99. The calculation is refreshed regularly with new filings.
What is the revenue of India Glycols Limited (INDIAGLYCO)?
India Glycols Limited reported trailing-twelve-month revenue of about ₹42.1B (latest available figure, as of Sep 27, 2026).
Does India Glycols Limited pay a dividend?
India Glycols Limited currently shows a dividend yield of about 1.04% relative to its recent price (as of Sep 27, 2026).
What is the intrinsic value of India Glycols Limited (INDIAGLYCO)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For India Glycols Limited it is ₹325.38 per share (as of Sep 27, 2026), against a price of ₹307.40. It is the blended result of 16 valuation models (cash flow, earnings, asset, dividend).
Is India Glycols Limited stock overvalued or undervalued in 2026?
As of Sep 27, 2026, INDIAGLYCO trades below its calculated fair value: price ₹307.40, fair value ₹325.38, a gap of about +6% (fairly valued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of INDIAGLYCO?
No. The price is what the market pays today (₹307.40); the fair value is what the company's own numbers justify (₹325.38). For India Glycols Limited the two are ₹17.98 per share apart. That gap is exactly why we show both numbers side by side.
How much is India Glycols Limited worth?
The market values India Glycols Limited at about ₹72.1B (market capitalisation, as of Sep 27, 2026). Per share that is ₹307.40; our models calculate a fair value of ₹325.38 per share.
What do the bullish and bearish scenarios say about INDIAGLYCO?
Our models span a range for India Glycols Limited: cautious scenario ₹227.76, base ₹325.38, optimistic ₹422.99 per share (as of Sep 27, 2026, price ₹307.40). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of INDIAGLYCO?
India Glycols Limited trades at a price-to-earnings ratio of 23.4 (as of Sep 27, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of ₹325.38 is built from several models across several years. Other multiples: P/B 2.5, P/S 1.7, EV/EBITDA 12.4.
How solid is the balance sheet of India Glycols Limited (INDIAGLYCO)?
Balance-sheet figures for India Glycols Limited (as of Sep 27, 2026): return on equity 11.3%, debt of 0.31 per unit of equity. They feed the Quality Score of 32/100, which measures business quality independently of the share price.
How far is INDIAGLYCO from its 52-week high?
India Glycols Limited trades at ₹307.40, about 74% below its 52-week high of ₹1,203 and 30% above the low of ₹236.20 (as of Sep 30, 2026). Distance from the high says nothing about value: that is what the fair value of ₹325.38 is for.
Which stocks are comparable to India Glycols Limited?
From the same area (Basic Materials) we also value Ningxia Baofeng Energy Group, Dow Inc, Hengli Petrochemical Co, Zangge Mining Company, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is India Glycols Limited stock attractive at the current price?
The data as of Sep 27, 2026: price ₹307.40, calculated fair value ₹325.38 (+6%), Quality Score 32/100, from 16 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of INDIAGLYCO calculated?
We run India Glycols Limited through 16 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of ₹325.38, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.7 % above its aggregate fair value. India Glycols Limited currently trades 6 % below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of India Glycols Limited (INDIAGLYCO)?
The closing price on Sep 30, 2026 was ₹307.40. Our model-based fair value is ₹325.38, about +6% upside (fairly valued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with India Glycols Limited right now?
The price sits close to our fair value, market and models broadly agree here, little valuation tension. A fairly wide model range (₹227.76 to ₹422.99) leaves room in how you read the outcome.
Key figures of India Glycols Limited
How large is the market capitalisation of India Glycols Limited (INDIAGLYCO)?
The market capitalisation of India Glycols Limited is ₹72.1B (≈ $752M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of India Glycols Limited (INDIAGLYCO)?
The price-to-sales ratio of India Glycols Limited is 1.63 (P/E × margin). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of India Glycols Limited (INDIAGLYCO)?
Earnings per share at India Glycols Limited are ₹45.97 (price ÷ EPS = P/E 23.4). Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of India Glycols Limited (INDIAGLYCO)?
The dividend yield of India Glycols Limited is 1.0% (payout 7.0%). Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of India Glycols Limited (INDIAGLYCO)?
The net margin of India Glycols Limited is 7.0% (fiscal year 2026). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of India Glycols Limited (INDIAGLYCO)?
The return on equity (ROE) of India Glycols Limited is 11.3% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of India Glycols Limited (INDIAGLYCO)?
On an EBIT basis the return on assets of India Glycols Limited is 8.1% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of India Glycols Limited (INDIAGLYCO)?
The operating margin of India Glycols Limited is 12.8% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at India Glycols Limited (INDIAGLYCO)?
Revenue at India Glycols Limited is growing +13.1% versus a year earlier (3y avg +16.9%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at India Glycols Limited (INDIAGLYCO)?
Earnings per share at India Glycols Limited are growing +31.9% versus a year earlier. How much earnings per share grew versus a year earlier.
How much free cash flow does India Glycols Limited (INDIAGLYCO) generate?
The free cash flow of India Glycols Limited is −₹1.7B (fiscal year 2026). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does India Glycols Limited (INDIAGLYCO) carry?
The net debt of India Glycols Limited is ₹16.4B (fiscal year 2026). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch India Glycols Limited in the live analysis
One click puts India Glycols Limited on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
